Author: Richard A Neher; Robert Dyrdak; Valentin Druelle; Emma B Hodcroft; Jan Albert
                    Title: Potential impact of seasonal forcing on a SARS-CoV-2 pandemic  Document date: 2020_2_17
                    ID: 3p2dl8yf_15
                    
                    Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint with probability x. Humans develop immune responses to CoVs rapidly and subsequent challenge studies show reduced susceptibility and less severe disease for a year (Callow et al., 1990) . Antibodies against SARS-CoV-1 persist for several years (Guo et al., 2020) . This is consistent with the observation that about 50% of all positive samples in our data come from patients.....
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: is the (which was not peer-reviewed) The copyright holder for this preprint with probability x. Humans develop immune responses to CoVs rapidly and subsequent challenge studies show reduced susceptibility and less severe disease for a year (Callow et al., 1990) . Antibodies against SARS-CoV-1 persist for several years (Guo et al., 2020) . This is consistent with the observation that about 50% of all positive samples in our data come from patients older than 10 years with a flat distribution across age groups. In analogy to the attack rate of seasonal influenza, we assume humans suffer from a seasonal CoV infection on average every 10 years (b = 0.1/y). Furthermore, we use R 0 = 2.3, a recovery rate of 0.2days −1 , and an incubation period of 5 days.
 
  Search related documents: 
                                Co phrase  search for related documents- age group and average 10 year: 1, 2
  - age group and challenge study: 1, 2, 3
  - age group and cov infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
  - age group and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
  - age group and incubation period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
  - age group and positive sample: 1, 2, 3, 4, 5, 6, 7
  - age group and recovery rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
  - age group and seasonal influenza: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
  - age group and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
  - attack rate and cov infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
  - attack rate and incubation period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
  - attack rate and positive sample: 1, 2, 3
  - attack rate and seasonal influenza: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
  - attack rate and seasonal influenza attack rate: 1, 2
  - attack rate and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
  - average 10 year and immune response: 1
  - average 10 year and incubation period: 1
  - challenge study and cov infection: 1, 2, 3, 4, 5
  - challenge study and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date